An immunogenetic basis for lung cancer risk.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38386728.
- Also identified by DOI 10.1126/science.adi3808 and PMC identifier 11998992.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental factors. However, the influence of genetic variation in immunosurveillance on cancer risk is not well understood. Leveraging population-level data from the UK Biobank and FinnGen, we show that heterozygosity at the <i>human leukocyte antigen (HLA)</i>-II loci is associated with reduced lung cancer risk in smokers. Fine-mapping implicated amino acid heterozygosity in the <i>HLA</i>-II peptide binding groove in reduced lung cancer risk, and single-cell analyses showed that smoking drives enrichment of proinflammatory lung macrophages and <i>HLA</i>-II+ epithelial cells. In lung cancer, widespread loss of <i>HLA</i>-II heterozygosity (LOH) favored loss of alleles with larger neopeptide repertoires. Thus, our findings nominate genetic variation in immunosurveillance as a critical risk factor for lung cancer.
Medical subject headings
- Histocompatibility Antigens Class II
- Lung Neoplasms
- Loss of Heterozygosity
- Immunologic Surveillance
- Genetic Predisposition to Disease